Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer

Vera Hirsh, Luis Paz-Ares, Michael Boyer, Rafael Rosell, Gary Middleton, Wilfried E E Eberhardt, Aleksandra Szczesna, Pavel Reiterer, Mansoor Saleh, Oscar Arrieta, Emilio Bajetta, Roy T. Webb, Johannes Raats, Rebecca J. Benner, Camilla Fowst, Sandra J. Meech, David Readett, Joan H. Schiller

Research output: Contribution to journalArticle

90 Scopus citations

Abstract

Purpose: This phase III study examined efficacy of the synthetic Toll-like receptor 9 - activating oligodeoxynucleotide PF-3512676 in combination with standard paclitaxel/carboplatin chemotherapy in patients with advanced non - small-cell lung cancer (NSCLC). Patients and Methods: Chemotherapy-naive patients with stage IIIB or IV NSCLC were randomly assigned (1:1) to receive up to six courses of paclitaxel/carboplatin (intravenous paclitaxel 200 mg/m 2 and carboplatin at area under the [concentration-time] curve 6 on day 1 of a 3-week cycle) alone (control arm) or in combination with 0.2 mg/kg subcutaneous PF-3512676 on days 8 and 15 (investigational arm). Primary end point was overall survival (OS). Results: Baseline demographics were similar across arms (N = 828). Most patients (88%) had stage IV disease. Median OS and median progression-free survival (PFS) were similar (OS: investigational arm, 10.0 months v control arm, 9.8 months; P = .56; PFS: investigational arm, 4.8 months v control arm, 4.7 months; P = .79). Most commonly reported PF-3512676-related adverse events (AEs) were mild-to-moderate local injection site reactions, pyrexia, and flu-like symptoms. In the investigational arm, grades 3 to 4 AEs, including neutropenia, thrombocytopenia, and anemia, were more frequent, and more patients had one or more sepsis-related AEs versus controls (17 v 3). At first interim analysis, the Data Safety Monitoring Committee recommended study discontinuation because of lack of incremental efficacy and more sepsis-related serious AEs in the PF-3512676 arm. Administration of PF-3512676, but not chemotherapy, was halted. Conclusion: Addition of PF-3512676 to paclitaxel/carboplatin did not improve OS or PFS versus paclitaxel/ carboplatin alone for first-line treatment of patients with advanced NSCLC but did increase toxicity. This regimen cannot be recommended for treating patients with advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)2667-2674
Number of pages8
JournalJournal of Clinical Oncology
Volume29
Issue number19
DOIs
StatePublished - Jul 1 2011

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Hirsh, V., Paz-Ares, L., Boyer, M., Rosell, R., Middleton, G., Eberhardt, W. E. E., Szczesna, A., Reiterer, P., Saleh, M., Arrieta, O., Bajetta, E., Webb, R. T., Raats, J., Benner, R. J., Fowst, C., Meech, S. J., Readett, D., & Schiller, J. H. (2011). Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. Journal of Clinical Oncology, 29(19), 2667-2674. https://doi.org/10.1200/JCO.2010.32.8971